ConvaTec is a global medical technology business focused on serving people and care givers in the areas of advanced wound care, ostomy care, continence and critical care and infusion care. We are committed to helping people with deeply personal and challenging medical conditions lead the life they want – helping them improve care for them and giving them greater confidence, freedom and mobility.
With a history of industry-leading innovation, our story begins in the laboratory of a brilliant scientist, Dr. James Chen of E.R. Squibb & Sons in the 1960s. His years of research exploring hundreds of formulations led to the invention of the first hydrocolloid medical adhesive for use in dental surgery. With this new technology in mind - our first product, Stomahesive® skin barrier, revolutionised ostomy care and established our reputation as an innovator of skin adhesives.
Since then, our product portfolio grew to include a complete ostomy care line and advanced wound care line. The same spirit of inventiveness and collaboration continues amongst our ~9,900 employees serving care givers, patients and customers globally.
Our Vision is to develop "pioneering trusted medical solutions to improve the lives we touch".
Our Values lie at the heart of everything we do, shaping the way we work every day:
Improve Care
Deliver Results
Grow Together
Own It
Do What’s Right
Find out more: https://www.convatecgroup.com/about-us/our-values/
With a history of industry-leading innovation, our story begins in the laboratory of a brilliant scientist, Dr. James Chen of E.R. Squibb & Sons in the 1960s. His years of research exploring hundreds of formulations led to the invention of the first hydrocolloid medical adhesive for use in dental surgery. With this new technology in mind - our first product, Stomahesive® skin barrier, revolutionised ostomy care and established our reputation as an innovator of skin adhesives.
Since then, our product portfolio grew to include a complete ostomy care line and advanced wound care line. The same spirit of inventiveness and collaboration continues amongst our ~9,900 employees serving care givers, patients and customers globally.
Our Vision is to develop "pioneering trusted medical solutions to improve the lives we touch".
Our Values lie at the heart of everything we do, shaping the way we work every day:
Improve Care
Deliver Results
Grow Together
Own It
Do What’s Right
Find out more: https://www.convatecgroup.com/about-us/our-values/
Location: United States, Pennsylvania, Reading
Employees: 5001-10000
Founded date: 1978
Investors 1
| Date | Name | Website |
| - | Avista Cap... | avistacap.... |
Mentions in press and media 10
| Date | Title | Description |
| 20.08.2025 | European defense stocks extend losses on resurging hopes for Ukraine ceasefire | LONDON — European defense stocks extended losses on Wednesday, after talks between U.S. President Donald Trump, Ukrainian President Volodymyr Zelenskyy and European leaders raised hopes for a pause or end to the conflict. The Stoxx Europe A... |
| 27.03.2025 | AGA Nanotech (UK) Wins the 2025 EWMA Innovation Competition | AGA Nanotech Wins EWMA Innovation Prize 2025 The winner AGA Nanotech was recognized for its groundbreaking Battlestar™ antimicrobial delivery system and awarded 10.000 EUR. BARCELONA, CATALONIA, SPAIN, March 27, 2025 /EINPresswire.com/ -- T... |
| 05.07.2022 | Convatec Find 87% of Patients with Long-Term Health Conditions Face Stigma in New Survey | “We already know that the impact of stigma on our patients cannot be understated,” said Karim Bitar, CEO, Convatec BRIDGEWATER, N.J. (PRWEB) July 05, 2022 According to new research, patients with long-term health conditions face stigma, amo... |
| 12.01.2022 | Further progress with ChloraSolv[®] roll out across Europe – market access activities in the Netherlands signal positive momentum | Further progress with ChloraSolv[®] roll out across Europe – market access activities in the Netherlands signal positive momentum Wed, Jan 12, 2022 08:00 CET RLS Global, a medical healthcare company based in Sweden, and ConvaTec, one of the... |
| 08.11.2021 | ConvaTec awarded contract for Advanced Wound Care Products from Vizient, Inc. 08 November 2021 | 08 November 2021 ConvaTec, a global medical technology and solutions company focused on improving patient outcomes across the continuum of care has extended their current contract for Advanced Wound Care Products with Vizient, Inc. The agre... |
| 01.10.2021 | ConvaTec : Announces Pricing of $500 Million 3.875% Senior Notes due 2029 01 October 2021 | 01 October 2021 London, England-September 30, 2021 - ConvaTec Group Plc (the "Company") announces that it has priced an offering of $500 million aggregate principal amount of senior notes due 2029 (the "Notes") intended ... |
| 30.09.2021 | ConvaTec : Announces Offering of $500 Million Senior Notes due 2029 30 September 2021 | 30 September 2021 London, England-September 30, 2021 - ConvaTec Group Plc (the "Company") announces that it has launched an offering of $500 million aggregate principal amount of senior notes due 2029 (the "Notes") inten... |
| 07.06.2019 | ConvaTec helps fund wound management research grants | ConvaTec (LON:CTEC) said today that it has joined the European Wound Management Association (EWMA) to launch three grants for wound management research. The grants will be available to nurses, doctors and scientists working in the field of ... |
| 02.05.2008 | Nordic Capital Fund VII and Avista Capital Partners Agree to Acquire ConvaTec Business for Approximately $4.1 billion | New York, NY, May 2, 2008 – Bristol-Myers Squibb Company (NYSE:BMY) announced today it has signed a definitive agreement to sell its ConvaTec business unit to Nordic Capital Fund VII (“Nordic Capital”) and Avista Capital Partners (“Avista”)... |
| - | European markets fall as mining stocks lead losses; Bayer shares at 20-year lows | This is CNBC’s live blog covering European markets. European markets were lower Tuesday as investors assess what U.S. President-elect Donald Trump’s return to the White House could mean for the region’s economy. The pan-European Stoxx 600 i... |